Clinical Evaluation of a New Molecular Test for the Detection of Organisms Causing Vaginitis and Vaginosis

In this prospective, observational, method comparison clinical study, the Xpert Xpress MVP test (MVP) was evaluated using both clinician-collected (CVS) and self-collected vaginal swabs (SVS) collected in a clinical setting. The study was conducted at 12 sites, including point-of-care (POC) settings, from geographically diverse locations in the United States. Participants were biologically female patients ≥ 14 years old with signs and/or symptoms of vaginitis/vaginosis. MVP test results for BV were compared to the BD MAX Vaginal Panel (BDVP). Results for Candida group and Candida glabrata and Candida krusei targets (species not differentiated) were assessed relative to yeast culture followed by mass spectrometry for species identification. Trichomonas vaginalis (TV) results were compared relative to a composite method that included results from the BDVP and InPouch TV culture. The investigational test demonstrated high positive percent agreement ranging from 93.6 to 99.0%, and negative percent agreement ranging from 92.1% to 99.8% for both CVS and SVS specimens, indicating it may be a valuable tool for the diagnosis of vaginitis/vaginosis in laboratory and POC settings.

Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

PURPOSE

Intratumorally injected Clostridium novyi-NT (nontoxic; lacking the alpha toxin), an attenuated strain of C. novyi, replicates within hypoxic tumor regions resulting in tumor-confined cell lysis and inflammatory response in animals, which warrants clinical investigation.

PATIENTS AND METHODS

This first-in-human study (NCT01924689) enrolled patients with injectable, treatment-refractory solid tumors to receive a single intratumoral injection of C. novyi-NT across 6 dose cohorts (1 × 10⁴ to 3 × 10⁶ spores, 3+3 dose-escalation design) to determine dose-limiting toxicities (DLT), and the maximum tolerated dose.

RESULTS

Among 24 patients, a single intratumoral injection of C. novyi-NT led to bacterial spores germination and the resultant lysis of injected tumor masses in 10 patients (42%) across all doses. The cohort 5 dose (1 × 10⁶ spores) was defined as the maximum tolerated dose; DLTs were grade 4 sepsis (n = 2) and grade 4 gas gangrene (n = 1), all occurring in three patients with injected tumors >8 cm. Other treatment-related grade ≥3 toxicities included pathologic fracture (n = 1), limb abscess (n = 1), soft-tissue infection (n = 1), respiratory insufficiency (n = 1), and rash (n = 1), which occurred across four patients. Of 22 evaluable patients, nine (41%) had a decrease in size of the injected tumor and 19 (86%) had stable disease as the best overall response in injected and noninjected lesions combined. C. novyi-NT injection elicited a transient systemic cytokine response and enhanced systemic tumor-specific T-cell responses.

CONCLUSIONS

Single intratumoral injection of C. novyi-NT is feasible. Toxicities can be significant but manageable. Signals of antitumor activity and the host immune response support additional studies of C. novyi-NT in humans.

Legionella: a Fascinating Bacterium Uncovered in the Twentieth Century

In July 1976, the American Legion held a conference at the Bellevue Stratford Hotel in Philadelphia, PA, to celebrate the nation's bicentennial. This convention resulted in transmission of a gram-negative bacterium to over 200 attendees, who developed a respiratory illness; 34 deaths were attributed to the infections. An investigation of the illness revealed a bacterium that had not been documented before. The disease became known as Legionnaires' disease, and the etiological agent was subsequently named Legionella pneumophila. This is the story of Legionella, with special emphasis on its ecological niche, the diagnosis of human infection, and its isolation from the environment. There are only a handful of diseases that debuted in the 20th or 21st century. They include Legionnaires' disease (the subject of this review), Lyme disease, AIDS, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and West Nile virus.

[Aplasia of retinal vessels in congenital cytomegaly]

Case report on a premature male infant, born in the 34th week of pregnancy with bronchopulmonary dysplasia, bronchitis, hepatitis, marked cortical and subcortical atrophy of the brain with enlargement of the inner and outer subarachnoid space, with severe cerebral motility disorders and convulsions. Blood serology showed rapidly increasing cytomegaly titers, which were also elevated in the serum of the mother. The ophthalmological examination revealed a hypoplastic, white papilla in both eyes. Neither retinal arteries nor veins were seen. The macula and retinal periphery were normal. There were no signs of acute or passed retinochorioiditis. Temporary opacification of the cornea was observed. In connection with the pediatric findings the authors interpret the aplasia of the retinal vessels and the hypoplasia of the optic nerve as a result of a cytomegaly infection prior to the 4th month of pregnancy, which prevented normal development of the vessels. The temporary opacity of the cornea could be a reaction of the corneal endothelium against the virus.